Notably, a recent clinical trial presented that the long-term albumin administration to patients with cirrhosis reduced systemic inflammation [8] and the cumulative incidence of complications of cirrhosis, including SBP and non-SBP bacterial infections [9,10]. This evidence concerns the gene ALB and bacterial infectious disease.